Maintenance drug to prevent relapse after stem cell transplant for T-cell leukemia or lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a maintenance treatment called chidamide, which is a pill that may help prevent the cancer from coming back after a stem cell transplant. It is for people with a certain type of T-cell leukemia or lymphoma who have achieved complete remission after the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have been diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL), specifically a subtype called early T-cell precursor (ETP).
- You have already had a stem cell transplant from a donor (allogeneic) and are in complete remission with full donor cell engraftment.
- You are generally able to perform daily activities (ECOG 0-2).
- Your kidneys, liver, and heart are functioning adequately.
- If you are of childbearing potential, you must be willing to use effective birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
This trial tests a drug called chidamide (Cidabenamide) as maintenance therapy after a stem cell transplant for people with intermediate or high-risk AML. The goal is to see if it helps prevent the leukemia from coming back.
This Phase 1/2 study tests whether chidamide can help prevent high-risk acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow transplant (allo-HSCT). Participants must already be in complete remission and have recovered blood counts after transplant.
This trial tests chidamide (a targeted medicine that affects how cells manage gene activity) in people whose peripheral T-cell lymphoma has come back or did not respond to treatment. It may help shrink measurable tumors and control the disease after prior therapies.
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
This trial tests two medicines given after a bone-marrow transplant to help lower the chance of acute myeloid leukemia (AML) coming back. It is aimed at people with higher-risk AML and checks safety along with whether the medicines can help prevent relapse.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.